Huang et al. [34] demonstrated that an anti-CD3/anti-CD133 bispecific antibody eliminated CD133high HCC CSCs in vitro and in vivo, reducing tumor growth. This evidence concerns the gene PROM1 and hepatocellular carcinoma.